J Runhaar1, C Sanchez2, S Taralla3, Y Henrotin4, S M A Bierma-Zeinstra5. 1. Erasmus MC University Medical Center Rotterdam, Department of General Practice, The Netherlands; D-BOARD Consortium, an European Committee FP7 Project, UK. 2. D-BOARD Consortium, an European Committee FP7 Project, UK; Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, CHU Sart-Tilman, Belgium. 3. Artialis SA, Liège, Belgium. 4. D-BOARD Consortium, an European Committee FP7 Project, UK; Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, CHU Sart-Tilman, Belgium. Electronic address: yhenrotin@ulg.ac.be. 5. Erasmus MC University Medical Center Rotterdam, Department of General Practice, The Netherlands; D-BOARD Consortium, an European Committee FP7 Project, UK; Erasmus MC University Medical Center Rotterdam, Department of Orthopedics, The Netherlands.
Abstract
OBJECTIVE: To determine the association between three fibulin-3 peptides and the incidence of radiographic and clinical knee osteoarthritis (OA). DESIGN: Women between 50 and 60 years, with a BMI ≥27 kg/m(2), free of knee OA, were recruited. Using binary logistic regression, the association between baseline concentration of serum fibulin (Fib)3-1, Fib3-2 and Fib3-3 and incidence of clinical and radiographic knee OA after 30 months of follow-up was evaluated. RESULTS: Baseline and follow-up measurements were available for 241 women with a mean age of 55.9 ± 3.2 years and mean BMI of 31.7 ± 3.6 kg/m(2). None of the concentrations of the three Fib3 epitopes were associated with the incidence of medial or lateral joint space narrowing (JSN) ≥1.0 mm or the incidence of Kellgren & Lawrence (K&L) grade ≥2 after 30 months. All three Fib3 epitopes were associated with the incidence of the clinical and radiographic ACR-criteria and Fib3-1 and Fib3-3 also with chronic pain at follow-up. When adjusted for the other Fib3 peptide concentrations, only Fib3-1 was significantly associated to the incidence of the American College of Rheumatology (ACR)-criteria (OR 3.2 [1.2-8.7]) and chronic pain at follow-up (OR 3.0 [1.2-7.7]). CONCLUSIONS: Baseline fibulin-3 concentrations are associated with the incidence of clinical knee OA among middle-aged overweight and obese women. Therewith, they meet the criteria of a prognostic biomarker according to the BIPED biomarker classification for OA. Further validation of the fibulin-3 epitopes seems warranted in order to better distinguish subgroups of individuals at increased risk for knee OA development.
OBJECTIVE: To determine the association between three fibulin-3 peptides and the incidence of radiographic and clinical knee osteoarthritis (OA). DESIGN:Women between 50 and 60 years, with a BMI ≥27 kg/m(2), free of knee OA, were recruited. Using binary logistic regression, the association between baseline concentration of serum fibulin (Fib)3-1, Fib3-2 and Fib3-3 and incidence of clinical and radiographic knee OA after 30 months of follow-up was evaluated. RESULTS: Baseline and follow-up measurements were available for 241 women with a mean age of 55.9 ± 3.2 years and mean BMI of 31.7 ± 3.6 kg/m(2). None of the concentrations of the three Fib3 epitopes were associated with the incidence of medial or lateral joint space narrowing (JSN) ≥1.0 mm or the incidence of Kellgren & Lawrence (K&L) grade ≥2 after 30 months. All three Fib3 epitopes were associated with the incidence of the clinical and radiographic ACR-criteria and Fib3-1 and Fib3-3 also with chronic pain at follow-up. When adjusted for the other Fib3 peptide concentrations, only Fib3-1 was significantly associated to the incidence of the American College of Rheumatology (ACR)-criteria (OR 3.2 [1.2-8.7]) and chronic pain at follow-up (OR 3.0 [1.2-7.7]). CONCLUSIONS: Baseline fibulin-3 concentrations are associated with the incidence of clinical knee OA among middle-aged overweight and obesewomen. Therewith, they meet the criteria of a prognostic biomarker according to the BIPED biomarker classification for OA. Further validation of the fibulin-3 epitopes seems warranted in order to better distinguish subgroups of individuals at increased risk for knee OA development.
Authors: Huub M de Visser; Christelle Sanchez; Simon C Mastbergen; Floris P J G Lafeber; Yves E Henrotin; Harrie Weinans Journal: Cartilage Date: 2018-01-24 Impact factor: 4.634